RelB/p50 Complexes Regulate Cytokine-Induced YKL-40 Expression.
Richmond, United States. In J Immunol, 13 Mar 2015
UNASSIGNED: The secreted protein, YKL-40, has been proposed as a biomarker of a variety of human diseases characterized by ongoing inflammation, including chronic neurologic pathologies such as multiple sclerosis and Alzheimer's disease.
Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.
Barcelona, Spain. In Brain, 13 Mar 2015
UNASSIGNED: Chitinase 3-like 1 (CHI3L1) has been proposed as a biomarker associated with the conversion to clinically definite multiple sclerosis in patients with clinically isolated syndromes, based on the finding of increased cerebrospinal fluid CHI3L1 levels in clinically isolated syndrome patients who later converted to multiple sclerosis compared to those who remained as clinically isolated syndrome.
Biomarkers of progression of chronic obstructive pulmonary disease (COPD).
Brisbane, Australia. In J Thorac Dis, Nov 2014
Examples of peripheral blood biological markers (biomarkers) include those associated with lung function (reduced CC-16), emphysema severity (increased adiponectin, reduced sRAGE), exacerbations and mortality [increased CRP, fibrinogen, leukocyte count, IL-6, IL-8, and tumor necrosis factor α (TNF-α)] including increased YKL-40 with mortality.
Biomarkers in connective tissue disease-associated interstitial lung disease.
Essen, Germany. In Semin Respir Crit Care Med, Apr 2014
Promising biomarkers are lung epithelium-derived proteins such as KL-6 (Krebs von den Lungen-6), SP-D (surfactant protein-D), SP-A (surfactant protein-A), YKL-40 (chitinase-3-like protein 1 [CHI3L1] or cytokines such as CCL18 [chemokine (C-C) motif ligand 18]).
Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma.
New York City, United States. In Front Oncol, 2013
We review the current concept of developing YKL-40 as one of the most promising serum markers for glioblastoma, the recent advances on understanding the role of YKL-40 in gliomagenesis, and the promising evidence emerging from preclinical models on using this protein as a target for anti-glioma therapy.